Source - SMW
Redx has appointed Andrew Saunders as its chief medical officer.

Saunders had worked in the oncology field for over 25 years and has extensive experience in all aspects of the clinical development of oncology drugs, the company said.

He would work with the research and development team at Redx, fronting the clinical development of RXC004, the company's lead drug candidate.

At 8:00am: (LON:REDX) Redx Pharma Plc share price was 0p at 18.25p